Selected Publications

Colomb F, Giron LB, Trbojevic-Akmacic I, Lauc G, Abdel-Mohsen M: Breaking the Glyco-Code of HIV Persistence and Immunopathogenesis. Curr HIV/AIDS Rep. 2019.

Colomb F, Giron LB, Premeaux TA, Mitchell BI, Niki T, Papasavvas E, Montaner LJ, Ndhlovu LC and Abdel-Mohsen M: Galectin-9 Mediates HIV Transcription by Inducing TCR-Dependent ERK Signaling. Front. Immunol. 2019.

Vadrevu SK, Trbojevic-Akmacic I, Kossenkov AV, Colomb F, Giron LB, Anzurez A, Lynn K, Mounzer K, Landay AL, Kaplan RC, Papasavvas E, Montaner LJ, Lauc G, Abdel-Mohsen M: Frontline Science: Plasma and immunoglobulin G galactosylation associate with HIV persistence during antiretroviral therapy. J. of Leuk. Bio. 104(3): 461-471, Sep 2018.

Abdel-Mohsen M, Kuri-Cervantes L, Grau-Exposito J, Spivak AM, Nell RA, Tomescu C, Vadrevu SK, Giron LB, Serra-Peinado C, Genescà M, Castellví J, Wu G, Del Rio Estrada PM, González-Navarro M, Lynn K, King CT, Vemula S, Cox K, Wan Y, Li Q, Mounzer K, Kostman J, Frank I, Paiardini M, Hazuda D, Reyes-Terán G, Richman D, Howell B, Tebas P, Martinez-Picado J, Planelles V, Buzon MJ, Betts MR, Montaner LJ: CD32 is expressed on cells with transcriptionally active HIV but does not enrich for HIV DNA in resting T cells. Science Transl. Med. 10(437), April 2018.

Abdel-Mohsen M, Chavez L, Tandon R, Chew GM, Deng X, Danesh A, Keating S, Lanteri M, Samuels ML, Hoh R, Sacha JB, Norris PJ, Niki T, Shikuma CM, Hirashima M, Deeks SG, Ndhlovu LC, Pillai SK: Human Galectin-9 Is a Potent Mediator of HIV Transcription and Reactivation. PLoS Patho. 12(6): e1005677, June 2016.

Abdel-Mohsen M, Wang C, Strain MC, Lada SM, Deng X, Cockerham LR, Pilcher CD, Hecht FM, Liegler T, Richman DD, Deeks SG, Pillai SK: Select host restriction factors are associated with HIV persistence during antiretroviral therapy. AIDS (London, England) 29(4): 411-20, February 2015.

Krarup AR, Abdel-Mohsen M, Schleimann MH, Vibholm L, Engen PA, Dige A, Wittig B, Schmidt M, Green SJ, Naqib A, Keshavarzian A, Deng X, Olesen R, Petersen AM, Benfield T, Østergaard L, Rasmussen TA, Agnholt J, Nyengaard JR, Landay A, Søgaard OS, Pillai SK, Tolstrup M, Denton PW: The TLR9 agonist MGN1703 triggers a potent type I interferon response in the sigmoid colon. Muc. Immun. 11(2): 449-461, March 2018.

Abdel-Mohsen M, Raposo RAS, Deng X, Li M, Liegler T, Sinclair E, Salama MS, Ghanem Hussam EDA, Hoh R, Wong JK, David M, Nixon DF, Deeks SG, Pillai SK: Expression profile of host restriction factors in HIV-1 elite controllers. Retrovirology 10: 106, October 2013.

Henrich TJ, Hatano H, Bacon O, Hogan LE, Rutishauser R, Hill A, Kearney MF, Anderson EM, Buchbinder SP, Cohen SE, Abdel-Mohsen M, Pohlmeyer CW, Fromentin R, Hoh R, Liu AY, McCune JM, Spindler J, Metcalf-Pate K, Hobbs KS, Thanh C, Gibson EA, Kuritzkes DR, Siliciano RF, Price RW, Richman DD, Chomont N, Siliciano JD, Mellors JW, Yukl SA, Blankson JN, Liegler T, Deeks SG: HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study. PLoS Med. 14(11): e1002417, November 2017.

Salantes DB, Zheng Y, Mampe F, Srivastava T, Beg S, Lai J, Li JZ, Tressler RL, Koup RA, Hoxie J, Abdel-Mohsen M, Sherrill-Mix S, McCormick K, Overton E T, Bushman FD, Learn GH, Siliciano RF, Siliciano JM, Tebas P, Bar KJ: HIV-1 latent reservoir size and diversity are stable following brief treatment interruption. J. of Clin. Invest. 128(7): 3102-3115, July 2018.